Loading...

ORKA ORUKA THERAPEUTICS INC Company Mergers 8-K Filing

RK T

RK

ORUKA THERAPEUTICS INC

(ORKA)

2025 8-K

Offering Update

Clinical Trial Results

Management Changes

Private Placement Details

License Agreement

License Agreement

Stockholder Meeting

Merger Completion

Management Changes

Private Placement

Merger Completion

Merger Announcement

Asset Purchase Agreement

Financial Results

Amendment Agreement

Financial Results

Retention Bonus Amendment

Departure of CEO and Appoin...

Merger Agreement

Lease Amendment

Resignations from Board of ...

Financial Results

Compensation and Annual Mee...

Retention Bonus Amendment

Financial Results

Earnings Releases

Financial Results

External Links:

Oruka Therapeutics has entered into a license agreement with Paragon Therapeutics for exclusive rights to develop and commercialize antibodies targeting IL-17A/F, with potential payments of up to $22 million based on milestones.

AI Assistant

ORUKA THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.